DrugPatentWatch Database Preview
Abbvie Company Profile
What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch?
ABBVIE has ninety approved drugs.
There are eighty-nine US patents protecting ABBVIE drugs.
There are one thousand three hundred and forty-one patent family members on ABBVIE drugs in sixty-seven countries and one hundred and nineteen supplementary protection certificates in fifteen countries.
Summary for Abbvie
| International Patents: | 1341 |
| US Patents: | 89 |
| Tradenames: | 78 |
| Ingredients: | 65 |
| NDAs: | 90 |
| Drug Master File Entries: | 1 |
| Patent Litigation for Abbvie: | See patent lawsuits for Abbvie |
Drugs and US Patents for Abbvie
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Abbvie Inc | ORILISSA | elagolix sodium | TABLET;ORAL | 210450-001 | Jul 23, 2018 | RX | Yes | No | 7,056,927 | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Abbvie | ULTANE | sevoflurane | LIQUID;INHALATION | 020478-001 | Jun 7, 1995 | AN | RX | Yes | Yes | 6,074,668*PED | ➤ Sign Up | Y | ➤ Sign Up | ||
| Abbvie | TRICOR (MICRONIZED) | fenofibrate | CAPSULE;ORAL | 019304-003 | Jun 30, 1999 | DISCN | Yes | No | ➤ Sign Up | ➤ Sign Up | |||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Abbvie
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Abbvie Endocrine Inc | LUPRON DEPOT-PED | leuprolide acetate | INJECTABLE;INJECTION | 020263-002 | Apr 16, 1993 | 4,652,441 | ➤ Sign Up |
| Abbvie | NIASPAN | niacin | TABLET, EXTENDED RELEASE;ORAL | 020381-004 | Jul 28, 1997 | 6,469,035 | ➤ Sign Up |
| Abbvie Endocrine Inc | LUPRON DEPOT-PED | leuprolide acetate | INJECTABLE;INJECTION | 020263-004 | Apr 16, 1993 | 5,631,021 | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for ABBVIE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Extended-release Tablets | 4 mg/ 240 mg | ➤ Subscribe | 2007-07-24 |
| ➤ Subscribe | Tablets | 100 mg | ➤ Subscribe | 2010-12-21 |
| ➤ Subscribe | Tablets | 400 mg and 600 mg | ➤ Subscribe | 2010-05-10 |
| ➤ Subscribe | Injection | 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials | ➤ Subscribe | 2008-11-28 |
| ➤ Subscribe | Tablets | 145 mg | ➤ Subscribe | 2007-10-19 |
| ➤ Subscribe | Capsules | 4 mcg | ➤ Subscribe | 2008-08-25 |
| ➤ Subscribe | Tablets | 5 mg/200 mg | ➤ Subscribe | 2005-05-27 |
| ➤ Subscribe | Gel | 1.62% | ➤ Subscribe | 2012-04-06 |
| ➤ Subscribe | Injection | 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial | ➤ Subscribe | 2009-08-04 |
| ➤ Subscribe | Extended-release Tablet | 500 mg | ➤ Subscribe | 2010-12-06 |
| ➤ Subscribe | Extended-release Tablets | 500 mg | ➤ Subscribe | 2005-02-08 |
| ➤ Subscribe | Delayed-release Capsules | 135 mg | ➤ Subscribe | 2009-09-01 |
| ➤ Subscribe | Extended-release Tablets | 1 mg/240 mg | ➤ Subscribe | 2008-02-20 |
| ➤ Subscribe | Oral Solution | 80 mg/20 mg per mL | ➤ Subscribe | 2014-06-19 |
| ➤ Subscribe | Tablets | 1 mg, 2 mg and 4 mg | ➤ Subscribe | 2004-10-04 |
| ➤ Subscribe | Capsules | 100 mg | ➤ Subscribe | 2012-10-31 |
| ➤ Subscribe | Tablets | 48 mg | ➤ Subscribe | 2008-07-01 |
| ➤ Subscribe | Capsules | 1 mcg and 2 mcg | ➤ Subscribe | 2008-10-14 |
| ➤ Subscribe | Tablets | 2.5 mg/200 mg | ➤ Subscribe | 2006-02-24 |
| ➤ Subscribe | Gel Metered-dose Pump | 1% | ➤ Subscribe | 2008-12-19 |
| ➤ Subscribe | Gel | 1.62% (1.25 g and 2.5 g packets) | ➤ Subscribe | 2013-06-19 |
| ➤ Subscribe | Injection | 2 mg/mL, 10 mL vial | ➤ Subscribe | 2009-08-12 |
| ➤ Subscribe | Extended-release Tablets | 250 mg | ➤ Subscribe | 2004-05-03 |
| ➤ Subscribe | Delayed-release Capsules | 45 mg | ➤ Subscribe | 2009-09-02 |
| ➤ Subscribe | Extended-release Tablets | 2 mg/180 mg and 2 mg/240 mg | ➤ Subscribe | 2007-11-09 |
| ➤ Subscribe | Tablets | 100 mg/25 mg | ➤ Subscribe | 2008-12-23 |
International Patents for Abbvie Drugs
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Germany | 10026698 | ➤ Sign Up |
| Canada | 2886502 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 9934762 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for Abbvie Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0055 | France | ➤ Sign Up | PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220 |
| /2017 | Austria | ➤ Sign Up | PRODUCT NAME: PIBRENTASVIR ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/17/1213 (MITTEILUNG) 20170728 |
| 0150015 00143 | Estonia | ➤ Sign Up | PRODUCT NAME: DASABUVIIR;REG NO/DATE: EU/1/14/983 19.01.2015 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
